Published in Blood Coagul Fibrinolysis on January 01, 2009
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis (2012) 4.62
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet (2009) 4.25
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol (2005) 3.19
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst (2007) 2.42
Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med (2011) 2.32
Imported Chikungunya Infection, Italy. Emerg Infect Dis (2007) 2.08
Reorganisation of an anticoagulation clinic using a telemedicine system: description of the model and preliminary results. Intern Emerg Med (2006) 2.07
Toxicities of targeted therapy and their management in kidney cancer. Eur Urol (2011) 1.76
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther (2004) 1.65
2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg (2013) 1.65
Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol (2007) 1.63
The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol (2002) 1.53
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma (2006) 1.48
Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol (2011) 1.48
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer (2010) 1.47
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet (2007) 1.47
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). Eur Urol (2012) 1.46
Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med (2005) 1.46
Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet (2005) 1.45
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis (2012) 1.45
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One (2011) 1.44
A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med (2013) 1.42
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer (2012) 1.41
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood (2003) 1.40
Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther (2013) 1.36
Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer (2010) 1.35
Update on the treatment of neuroendocrine tumors. Expert Rev Anticancer Ther (2003) 1.33
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. World J Emerg Surg (2011) 1.29
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol (2006) 1.28
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer (2011) 1.28
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol (2011) 1.27
Complicated intra-abdominal infections in Europe: a comprehensive review of the CIAO study. World J Emerg Surg (2012) 1.24
The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica (2011) 1.23
Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol (2012) 1.19
Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res (2007) 1.19
Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. Nucl Med Commun (2007) 1.19
Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients. PLoS One (2012) 1.18
Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother (2009) 1.17
The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat (2014) 1.17
Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother (2012) 1.16
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol (2005) 1.14
HIV-1 Tat protein enhances RANKL/M-CSF-mediated osteoclast differentiation. Biochem Biophys Res Commun (2010) 1.12
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother (2010) 1.11
Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? Crit Care (2009) 1.11
SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res (2005) 1.11
Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis (2006) 1.09
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol (2007) 1.09
68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun (2009) 1.09
Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet (2004) 1.07
The plasmablasts in Castleman disease. Am J Clin Pathol (2013) 1.07
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res (2008) 1.06
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun (2005) 1.06
Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. Medicine (Baltimore) (2014) 1.05
Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. Int J Infect Dis (2010) 1.05
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer (2006) 1.04
Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. Thromb J (2014) 1.04
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida. Virulence (2012) 1.03
Surveillance of hospital-acquired infections: a model for settings with resource constraints. Am J Infect Control (2006) 1.03
Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia. Am J Hematol (2006) 1.03
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer (2010) 1.02
Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol (2011) 1.02
Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database. J Antimicrob Chemother (2013) 1.02
Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin Pharmacother (2010) 1.02
The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis (2006) 1.02
Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med (2010) 1.02
Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother (2006) 1.01
Infective endocarditis in chronic haemodialysis patients: an increasing clinical challenge. Eur Heart J (2007) 1.00
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol (2007) 0.99
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging (2008) 0.99
FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis. Eur J Nucl Med Mol Imaging (2012) 0.98
Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol (2003) 0.98
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology (2012) 0.98
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother (2005) 0.98
Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother (2003) 0.98
18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging (2005) 0.98
Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf (2011) 0.98
Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res (2011) 0.97
Pathotype and susceptibility profile of a community-acquired methicillin-resistant Staphylococcus aureus strain responsible for a case of severe pneumonia. Diagn Microbiol Infect Dis (2009) 0.97
FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas (2015) 0.96
Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol (2015) 0.96
Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. PLoS One (2013) 0.95
Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI). BMC Infect Dis (2014) 0.95
A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study. Eur J Gastroenterol Hepatol (2012) 0.95